7479-05-2

Basic information

• Product Name: H-D-TRP-OET HCL
• Synonyms: Ethyl 2-amino-3-(1H-indol-3-yl)propanoate;D-TRYPTOPHAN ETHYL ESTER HYDROCHLORIDE;Ethyl2-amino-3-(1H-indol-3-yl)propanoateHCl;L-Tryptophan ethyl
• CAS NO: 7479-05-2
• Molecular Formula: C13H17ClN2O2
• Molecular Weight: 268.74
• EINECS: 231-285-1
• Product Categories: Tryptophan [Trp, W]
• Mol File: 7479-05-2.mol
• Article Data: 32

Chemical Properties

• Melting Point: 218 °C
• Boiling Point: 401.2 °C at 760 mmHg
• Flash Point: 196.4 °C
• Appearance: /
• Density: 1.211 g/cm³
• Vapor Pressure: 1.01E-07mmHg at 25°C
• PKA: 17.03±0.30(Predicted)
• CAS DataBase Reference: H-D-TRP-OET HCL(CAS DataBase Reference)
• NIST Chemistry Reference: H-D-TRP-OET HCL(7479-05-2)
• EPA Substance Registry System: H-D-TRP-OET HCL(7479-05-2)

Safety Data

• Hazard Codes: Xi:Irritant
• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S37/39:Wear suitable g
• Hazardous Substances Data: 7479-05-2(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 71, p. 3079, 1949 DOI: 10.1021/ja01177a039

InChI:InChI=1/C13H16N2O2.ClH/c1-2-17-13(16)11(14)7-9-8-15-12-6-4-3-5-10(9)12;/h3-6,8,11,15H,2,7,14H2,1H3;1H/t11-;/m1./s1

Upstream product

• 220906-02-5 (2R,5S)-3,6-diethoxy-2-isopropyl-5-[2-(trimethylsilyl)-3-indolyl]methyl-2,5-dihydropyrazine 
• 41844-69-3 N-benzyloxycarbonyl-L-tryptophan ethyl ester 
• 2899-28-7 L-tryptophan ethyl ester hydrochloride 
• 125109-04-8 ethyl α-(hydroxyimino)-β-(N-methylindol-3-yl)propanoate 
• 63971-99-3 ethyl 3-(1H-indol-3-yl)-2-nitropropanoate 
• 54-12-6 Trp 
• 64-17-5 ethanol 
• 15142-91-3 rac-3-(1H-indol-3-yl)-2-methylpropanoic acid 
• 101427-38-7 2,2'-dinitro-2,2'-(2-aza-propanediyl)-di-malonic acid tetraethyl ester 
• 120-72-9 indole 
• 73-22-3 L-Tryptophan 
• 220906-01-4 (2R,5S)-3,6-diethoxy-2-isopropyl-5-[3-(trimethylsilyl)prop-2-ynyl]2,5-diydropyrazine 
• 615-43-0 2-iodophenylamine 
• 6519-66-0 DL-tryptophan ethyl ester 

Downstream Products

• 3262-57-5 [(benzyloxy)carbonyl]glycyl-L-tryptophan 
• 73-22-3 L-Tryptophan 
• 81571-34-8 DAVLB-L-Trp-OEt 
• 81600-06-8 C₅₇H₇₀N₆O₉ 
• 164119-87-3 Cbz-Leu-Trp-OEt 
• 1026542-86-8 (S)-2-[(1-tert-Butoxycarbonylamino-cyclopentanecarbonyl)-amino]-3-(1H-indol-3-yl)-propionic acid ethyl ester 
• 196394-99-7 (S)-2-(2-Acetylsulfanylmethyl-3-biphenyl-4-yl-propionylamino)-3-(1H-indol-3-yl)-propionic acid ethyl ester 
• 196394-95-3 (S)-2-[2-Acetylsulfanylmethyl-3-(4-bromo-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionic acid ethyl ester 
• 196394-78-2 (S)-2-[2-Acetylsulfanylmethyl-3-(3-bromo-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionic acid ethyl ester 
• 196394-84-0 (S)-2-(2-Acetylsulfanylmethyl-3-biphenyl-3-yl-propionylamino)-3-(1H-indol-3-yl)-propionic acid ethyl ester 
• 196395-03-6 (S)-2-[2-Acetylsulfanylmethyl-3-(4-benzyloxy-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionic acid ethyl ester 
• 609360-86-3 (S)-2-[(E)-2-(Benzyloxycarbamoyl-methyl)-4-methyl-pent-2-enoylamino]-3-(1H-indol-3-yl)-propionic acid ethyl ester 

Relevant articles and documents

Harmine-based dual inhibitors targeting histone deacetylase (HDAC) and DNA as a promising strategy for cancer therapy

Overexpression of histone deacetylases (HDACs) are observed in different types of cancers, but histone deacetylase inhibitors (HDACIs) have not shown significant efficacy as monotherapy against solid tumors. Recently, studies demonstrated that it is promi

Design, synthesis and evaluation of novel β-carboline ester analogues as potential anti-leishmanial agents

Leishmaniasis is one of today's most neglected diseases. The emergence of new anti-leishmanial therapies emphasizes several study groups funded by the World Health Organization. The present investigation will focus on the research to determine a few new potential derivatives of β-carboline ester derivatives against leishmaniasis. The in-silico predicted ADMET properties of most of the titled compounds are in an acceptable range and having drug like properties. Among all the tested analogs, compound ES-3 (EC50 3.36 μM; SI > 29.80) showed comparable and equipotent anti-leishmanial activity as that of standard drug miltefosine (EC50 4.80 μM; SI > 20.80) against amastigote forms of the tested L. infantum strain. Two compounds ES-6 and ES-10 exhibited significant activity with EC50 10.16, 13.56 μM; SI > 4.90, 7.37, respectively. In-silico based molecular docking and dynamics study of the significantly active analog also performed to study the putative binding mode, interaction pattern at the active site of the target leishmanial trypanothione reductase enzyme as well as stability of the target-ligand complex. The changes in the conformation of molecules during MD (frame wise trajectory analysis) provided new insights for the development of novel potent molecules. These findings will further give insight that will help modify the compound ES-3 for better potency and the design of novel inhibitors for leishmaniasis. Communicated by Ramaswamy H. Sarma.

A class of DL-tryptophan compounds, preparation method and applications thereof

The invention provides a DL-tryptophan compound represented by a general formula I or a pharmaceutically acceptable salt thereof, a preparation method and applications thereof, especially applicationsin preparation of RANKL inhibitors. According to the DL-tryptophan compound or the pharmaceutically acceptable salt thereof, an OPG-RANKL-RANK signal system can be intervened by inhibiting the interaction of RANKL-RANK, and the activity of RANKL in osteoclast precursor cells is regulated and controlled, so that formation of osteoclasts is inhibited, and bone resorption is reduced; and the DL-tryptophan compound or the pharmaceutically acceptable salt thereof is expected to play a role in preventing and treating bone metabolic diseases, and brings good news to bone metabolic disease patients.